Insider Trading Alert - RGEN, DVA And FLT Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, May 19, 2015, 105 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $1,088.06 to $96,569,200.00.

Highlighted Stocks Traded by Insiders:

Repligen (RGEN) - FREE Research Report

Rusche James R, who is Senior Vice President at Repligen, sold 15,000 shares at $41.32 on May 19, 2015. Following this transaction, the Senior Vice President owned 96,849 shares meaning that the stake was reduced by 13.41% with the 15,000-share transaction.

The shares most recently traded at $41.55, up $0.23, or 0.55% since the insider transaction. Historical insider transactions for Repligen go as follows:

  • 4-Week # shares bought: 35,000
  • 4-Week # shares sold: 170,000
  • 12-Week # shares bought: 35,000
  • 12-Week # shares sold: 270,869
  • 24-Week # shares bought: 35,000
  • 24-Week # shares sold: 270,869

The average volume for Repligen has been 440,200 shares per day over the past 30 days. Repligen has a market cap of $1.4 billion and is part of the health care sector and drugs industry. Shares are up 110.66% year-to-date as of the close of trading on Tuesday.

Repligen Corporation, a life sciences company, develops, manufactures, and markets consumable bioprocessing products for use in the production of monoclonal antibodies and other biologic drugs. The company has a P/E ratio of 198.7. Currently, there are 2 analysts who rate Repligen a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on RGEN - FREE

TheStreet Quant Ratings rates Repligen as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins and solid stock price performance. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Repligen Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you liked this article you might like

Drug Stocks Find Trump Animus a Bitter Pill

5 Health Care Stocks Set to Bounce

Repligen Has More Upside Ahead

Repligen Has More Upside Ahead

Trade-Ideas: Repligen (RGEN) Is Today's Weak On High Relative Volume Stock

Today's Dead Cat Bounce Stock Is Repligen (RGEN)